Article
Cell Biology
Kaixuan Guo, Cheng Liu, Juanyi Shi, Cong Lai, Ze Gao, Jiawen Luo, Zhuohang Li, Zhuang Tang, Kuiqing Li, Kewei Xu
Summary: Dysregulated HMMR is associated with poor prognosis in prostate cancer. HMMR promotes PCa proliferation and metastasis through interacting with AURKA and activating the mTORC2/AKT pathway. Moreover, sustained activation of mTORC2/AKT pathway upregulates E2F1, which further promotes HMMR transcription, forming a positive feedback loop that contributes to PCa progression. Administration of mTOR inhibitor partially antagonizes HMMR-mediated PCa progression.
CELL DEATH DISCOVERY
(2023)
Article
Oncology
Tufia C. Haddad, Vera J. Suman, Antonino B. D'Assoro, Jodi M. Carter, Karthik V. Giridhar, Brendan P. McMenomy, Katelyn Santo, Erica L. Mayer, Meghan S. Karuturi, Aki Morikawa, P. Kelly Marcom, Claudine J. Isaacs, Sun Young Oh, Amy S. Clark, Ingrid A. Mayer, Khandan Keyomarsi, Timothy J. Hobday, Prema P. Peethambaram, Ciara C. O'Sullivan, Roberto A. Leon-Ferre, Minetta C. Liu, James N. Ingle, Matthew P. Goetz
Summary: This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase objective tumor response rates (ORRs) or progression-free survival (PFS) in endocrine-resistant metastatic breast cancer (MBC).
Article
Biochemistry & Molecular Biology
Shiao-Ya Hong, Yi-Chun Lu, Shih-Hsin Hsiao, Yu-Rung Kao, Meng-Hsuan Lee, Yi-Ping Lin, Cheng-Yi Wang, Cheng-Wen Wu
Summary: This study reveals that CBLC is involved in cell cycle regulation by stabilizing AURKA through ubiquitination, and targeting CBLC can inhibit tumor growth and enhance sensitivity to paclitaxel in LAD cells.
Review
Oncology
Fuping Wang, Haotian Zhang, Haitao Wang, Tian Qiu, Binghong He, Qiong Yang
Summary: Breast cancer is commonly associated with high expression of AURKA and HSP90, which leads to drug resistance. Targeting these factors with inhibitors can improve treatment specificity and efficiency.
Review
Biochemistry & Molecular Biology
Ruijuan Du, Chuntian Huang, Kangdong Liu, Xiang Li, Zigang Dong
Summary: AURKA is overexpressed in cancers and regulates substrate functions through phosphorylation, participating in various classic oncogenic pathways.
Article
Multidisciplinary Sciences
Jin-Gyeong Park, Hanul Jeon, Sangchul Shin, Chiman Song, Hyomin Lee, Nak-Kyoon Kim, Eunice EunKyeong Kim, Kwang Yeon Hwang, Bong-Jin Lee, In-Gyun Lee
Summary: This study identified a conserved region of CEP192 that interacts with AURKA and revealed the structural basis for CEP192-mediated regulation of AURKA at the centrosome. This regulation is distinct from TPX2-mediated regulation on the spindle microtubule.
Review
Endocrinology & Metabolism
Amber J. Kiliti, Ghada M. Sharif, Mary Beth Martin, Anton Wellstein, Anna T. Riegel
Summary: Estrogen receptor alpha (ERα) plays a crucial role in the initiation and progression of most breast cancers. It regulates gene transcription through recruitment of coregulators, including Amplified in Breast Cancer 1 (AIB1). AIB1, an oncogene overexpressed in some breast cancers, is involved in tumor progression and resistance to endocrine therapy. This review provides an overview of the normal and pathological functions of AIB1, its actions dependent and independent of ERα, as well as its genomic conservation and protein evolution. The efforts to target AIB1 in the treatment of breast cancer are also discussed.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Jing Tang, Lirui Yang, Yafei Li, Xuelian Ning, Anita Chaulagain, Tianzhen Wang, Dong Wang
Summary: The study found that ARID3A expression increased in CRC tissues, potentially acting as a tumor-promoting factor. Overexpression of ARID3A can enhance tumor cell proliferation, migration, and invasion, targeting AURKA to facilitate the malignant phenotype of CRC cells. The ratio of ARID3A and AURKA could serve as a potential biomarker for predicting prognosis in CRC.
Article
Oncology
Fei Fei, Gene P. Siegal, Shi Wei
Summary: The study analyzed clinicopathologic features and clinical outcomes of ER-low-positive breast cancers. ER-low-positive tumors showed significantly better prognosis compared to ER-negative tumors, with overlapping survival outcomes with ER-positive tumors in the entire cohort.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Biology
Italia Anna Asteriti, Federica Polverino, Venturina Stagni, Valentina Sterbini, Camilla Ascanelli, Francesco Davide Naso, Anna Mastrangelo, Alessandro Rosa, Alessandro Paiardini, Catherine Lindon, Giulia Guarguaglini
Summary: AurkA kinase is frequently overexpressed in tumors and its nuclear localization in interphase is correlated with its oncogenic potential. The mechanisms leading to AurkA nuclear accumulation are poorly explored, but it is influenced by the cell cycle phase and nuclear export, and not by its kinase activity. Co-overexpression of AURKA and TPX2 or impairment of proteasome activity can induce AurkA nuclear accumulation.
LIFE SCIENCE ALLIANCE
(2023)
Article
Medicine, General & Internal
Ioannis A. Voutsadakis
Summary: This study investigates ER-positive/HER2-negative or luminal breast cancers with high mutation numbers and compares them with cancers of the same subtype and low mutation numbers. The results show that breast cancers with high mutation numbers have a higher prevalence of certain genetic mutations and DNA damage response genes. However, the prognosis of these breast cancers is not significantly different compared to those with lower mutation counts. These findings provide information on the suitability of these cancers for immunotherapy and potential combination therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Jamie O. Brett, Lauren L. Ritterhouse, Erik T. Newman, Kelly E. Irwin, Megan Dawson, Lianne Y. Ryan, Laura M. Spring, Miguel N. Rivera, Jochen K. Lennerz, Dora Dias-Santagata, Leif W. Ellisen, Aditya Bardia, Seth A. Wander
Summary: In this case series, four patients with HR+ metastatic breast cancer carrying ESR1 fusion genes were studied, and therapeutic strategies were discussed. The study found that CDK4/6 inhibition may be effective against ESR1-FUS with functional ligand-binding domain swaps.
Article
Chemistry, Multidisciplinary
Fang Liu, Xuan Wang, Jianli Duan, Zhijie Hou, Zhouming Wu, Lingling Liu, Hanqi Lei, Dan Huang, Yifei Ren, Yue Wang, Xinyan Li, Junxiao Zhuo, Zijian Zhang, Bin He, Min Yan, Huiming Yuan, Lihua Zhang, Jinsong Yan, Shijun Wen, Zifeng Wang, Quentin Liu
Summary: This study introduces a PROTAC cocktail that effectively degrades AURKA in acute myeloid leukemia cells, inhibits AML stem cells, and induces AML regression in mouse models and primary patient cells. This spatial-temporal drug administration strategy shows promise in eliminating the multifaceted functions of oncoproteins and preventing cancer stem cell-mediated drug resistance.
Article
Cell Biology
Xiao-Wei Zhang, Jing-Yi Li, Lin Li, Wen-Qian Hu, Yan Tao, Wen-Yan Gao, Zi-Nuo Ye, Hao-Yuan Jia, Jia-Nan Wang, Xiao-Kang Miao, Wen-Le Yang, Rui Wang, Ling-Yun Mou
Summary: The increased expression of the cell surface receptor NK1R is associated with the progression and prognosis of treatment-related NEPC. AR inhibition enhances NK1R expression, promoting tNEPC development through the PKC & alpha;-AURKA/N-Myc pathway. Activated NK1R promotes NE transdifferentiation, cell proliferation, invasion, and enzalutamide resistance in prostate cancer cells. Targeting NK1R can inhibit NE transdifferentiation and tumor formation in vitro and in vivo.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Hengqiang Zhao, Yiping Gong
Summary: Single estrogen receptor (ER)+ and progesterone receptor (PR)+ tumors account for about 10% of all breast cancers. The prognosis of these tumors varies based on HER2 status, with single ER+ and PR+ patients showing different survival outcomes in different HER2 subtypes. In HER2- subtype, single PR+ patients had poorer prognoses than single ER+ patients, while in HER2+ subtype, single ER+ and PR+ patients showed similar prognoses compared with ER-PR- patients.
FRONTIERS IN ONCOLOGY
(2021)
